CombiGene

CombiGene AB, based in Sweden, specializes in developing innovative gene therapies for patients with severe, life-altering neurological diseases, particularly epilepsy, where current treatments are inadequate. The company's approach involves using an adeno-associated viral vector to deliver a combination of neuropeptide Y (NPY) and its receptor Y2 directly to the seizure's origin in the brain. Preclinical studies have shown promising results, and the next phase involves mandatory safety studies. If these are successful, human trials can commence following the completion of good manufacturing practice (GMP) production of CG01, the company's lead therapy.